6CYM

Reversible Covalent Direct Thrombin Inhibitors

6CYM の概要

• エントリーDOI: 10.2210/pdb6cym/pdb
• 分子名称: Prothrombin, 2-methoxybenzoic acid, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (6 entities in total)
• 機能のキーワード: hydrolase, blood coagulation, plasma, calcium-binding, glycoprotein, serine protease, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 66739.35

構造登録者

Sivaraja, M.,Williams, D.C. (登録日: 2018-04-06, 公開日: 2018-05-09, 最終更新日: 2024-11-13)

主引用文献

Sivaraja, M.,Pozzi, N.,Rienzo, M.,Lin, K.,Shiau, T.P.,Clemens, D.M.,Igoudin, L.,Zalicki, P.,Chang, S.S.,Estiarte, M.A.,Short, K.M.,Williams, D.C.,Datta, A.,Di Cera, E.,Kita, D.B.
Reversible covalent direct thrombin inhibitors.
PLoS ONE, 13:e0201377-e0201377, 2018

PubMed Abstract: In recent years, the traditional treatments for thrombotic diseases, heparin and warfarin, are increasingly being replaced by novel oral anticoagulants offering convenient dosing regimens, more predictable anticoagulant responses, and less frequent monitoring. However, these drugs can be contraindicated for some patients and, in particular, their bleeding liability remains high.

PubMed: 30071045
DOI: 10.1371/journal.pone.0201377

実験手法

X-RAY DIFFRACTION (2.9 Å)